Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...

Other companies, like Indiana-based Eli Lilly and California-based Structure Therapeutics, are also working on small-molecule obesity drugs, Traggis said. "For us, coming in a little bit later ...

To make the GLP-1 hormone "long-acting" her team found a way to attach a fatty acid to the molecule. She compares this structure to a steak — it's a one-two punch of protein and fat, protecting ...

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

India’s apex drug regulating authority, the Central Drugs Standard Control Organisation (CDSCO), has approved 19 new drugs so ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The most recent, Ozempic and ... current price of $6.92. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for chronic ...